Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies. After patients with acute monocytic leukemia (AML) ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay.

H OUSTON -- Complete response (CR) rates in relapsed/refractory NPM1 -mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.

Kura Oncology and Kyowa Kirin announced promising results from the KOMET-007 trial, which evaluated ziftomenib, an oral investigational menin inhibitor, in combination with standard chemotherapy for ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of ...